₹14,000 per month weight-loss shot is here to cash in on India’s obesity crisis
India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...
Endpoints News2d
No­vo Nordisk says new ear­ly R&D struc­ture will ‘fu­ture-proof’ its busi­ness
Novo Nordisk is reorganizing its research and early development unit in an effort to “future-proof the organization” and ...
STAT3d
Tapping the potential of GLP-1 drugs requires integrated care and overcoming inequities, executives say
At STAT's Breakthrough Summit East, the CEOs of Ro and Included Health said the the U.S. health care system poses obstacles ...
Fierce Biotech3d
'Not a cost-cutting exercise': Novo Nordisk CSO explains rationale behind pharma's R&D shake-up
Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...
Novo Nordisk (NVO) to be ‘Market Leader’ Despite ‘Horrifying’ Declines
We recently published a list of 10 Stocks Market Experts are Talking About These Days. In this article, we are going to take ...
Why Novo Nordisk Stock Outpaced the Market on Tuesday
Novo Nordisk (NYSE: NVO), the Danish company best known as the maker of weight loss drug Wegovy, expanded a little on the ...
Fierce Pharma5d
Lilly, J&J, Pfizer and Sanofi back Teva fight against IRA drug negotiation program
As a drugmaker depending heavily on sales of both branded and non-branded products, Teva has said that it is uniquely affected by how medicines are selected for the Medicare drug price negotiation | ...